CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.
Saved in:
| Title: | CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis. |
|---|---|
| Authors: | Rampotas A; Cancer Institute, University College London, WC1E 6DD London, UK., Wong ZC; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK.; National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA., Gannon I; Cancer Institute, University College London, WC1E 6DD London, UK., Brierley CK; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK.; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, OX3 7LE Oxford, UK., Shen Y; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Benlabiod C; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Chee A; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, OX3 7LE Oxford, UK., Khan S; Cancer Institute, University College London, WC1E 6DD London, UK., Hayder N; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Cheung GW; Cancer Institute, University College London, WC1E 6DD London, UK., Mitsikakou M; Cancer Institute, University College London, WC1E 6DD London, UK., Murphy E; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Ferrari M; Autolus Ltd., W12 7FP London, UK., Bulek A; Autolus Ltd., W12 7FP London, UK., Rodriguez-Romera A; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Murphy L; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Olijnik AA; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Rodriguez-Justo M; Cancer Institute, University College London, WC1E 6DD London, UK., Marty C; INSERM UMR1287 Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France., Hitchcock I; University of York, YO10 5DD York, UK., Royston D; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, OX3 9DU Oxford, UK., Mead AJ; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK.; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, OX3 7LE Oxford, UK., Khan AO; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK., Lambert J; University College London Hospitals NHS Foundation Trust, NW1 2BU London, UK., Roddie C; Cancer Institute, University College London, WC1E 6DD London, UK., Psaila B; MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK.; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, OX3 7LE Oxford, UK.; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, OX3 7DQ Oxford, UK., Pule MA; Cancer Institute, University College London, WC1E 6DD London, UK. |
| Source: | Science translational medicine [Sci Transl Med] 2026 Jul; Vol. 18 (856), pp. eadz3553. Date of Electronic Publication: 2026 Jul 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1946-6242 |
|---|---|
| DOI: | 10.1126/scitranslmed.adz3553 |
